Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
29.44
+0.10 (0.34%)
Jan 20 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 28.91 - 29.52
52 week 24.47 - 44.38
Open 29.32
Vol / Avg. 606,982.00/598,243.00
Mkt cap 1.20B
P/E 20.82
Div/yield     -
EPS 1.41
Shares 40.50M
Beta 1.04
Inst. own 90%
Mar 6, 2017
Emergent BioSolutions Inc at Cowen Health Care Conference Add to calendar
Feb 23, 2017
Q4 2016 Emergent BioSolutions Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 13, 2017
Emergent BioSolutions Inc at Wells Fargo Specialty and Generic Drug Summit Add to calendar
Jan 10, 2017
Emergent BioSolutions Inc at JPMorgan Healthcare Conference
Dec 8, 2016
Emergent BioSolutions Inc Business Update Call
Nov 7, 2016
Q3 2016 Emergent BioSolutions Inc Earnings Call - Webcast
Nov 7, 2016
Q3 2016 Emergent BioSolutions Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 14.27% 12.03%
Operating margin 24.82% 18.37%
EBITD margin - 25.13%
Return on average assets 8.22% 6.36%
Return on average equity 13.40% 10.36%
Employees 1,292 -
CDP Score - -

Address

400 Professional Dr Ste 400
GAITHERSBURG, MD 20879-3457
United States - Map
+1-240-6313200 (Phone)
+1-240-6313203 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity.

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Daniel J. Abdun-Nabi President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Executive Vice President - Corporate Services Division, Chief Financial Officer and Treasurer
Age: 58
Bio & Compensation  - Reuters
Adam Havey Executive Vice President and President - BioDefense Division
Age: 45
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 60
Bio & Compensation  - Reuters
Kathryn C. Zoon Ph.D. Director
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Jerome M. Hauer Independent Director
Age: 64
Bio & Compensation  - Reuters